Comparison of Different ROS1 Immunohistochemistry Clones and Consistency with Fluorescence In Situ Hybridization Results in Non-Small Cell Lung Carcinoma
-
Published:2023-09-13
Issue:5
Volume:40
Page:344-350
-
ISSN:2146-3123
-
Container-title:Balkan Medical Journal
-
language:
-
Short-container-title:Balkan Med J
Author:
Dülger Onur,Öz Büge
Publisher
Galenos Yayinevi
Reference32 articles.
1. Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res. 2017;6:550-559. [CrossRef]
2. VanderLaan PA, Rangachari D, Majid A, et al. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018;116:90-95. [CrossRef]
3. Duffy MJ, O'Byrne K. Tissue and blood biomarkers in lung cancer: A Review. Adv Clin Chem. 2018;86:1-21. [CrossRef]
4. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol. 2013;31:1039-1049. [CrossRef]
5. Ahmed Y, Dennehy C, Jordan E, Calvert P. Precision medicine in targeting ROS1-rearranged non-small cell lung cancer. J Cancer Sci Ther. 2019;11:224-227. [CrossRef]